TMS Icon

Global Thalassaemia Review

Introduction

The first-ever TIF-developed Global Review of Thalassaemia!

The Global Thalassaemia Review was put together by TIF, in collaboration with the World Health Organisation (WHO), as a collection of independent reports to document the existing situation with thalassaemia across the world in the context of the various components of public health, clinical, and social services, which are deemed essential for patients’ survival and wellbeing.

This video briefly introduces the Review’s key objectives and findings, highlighting the huge heterogeneity and inequality that people affected by thalassaemia still encounter in terms of access to quality healthcare services in many countries across the world.

Explore the Report

The 2025 edition of the Global Thalassaemia Review (GTR), published by the Thalassaemia International Federation (TIF), represents the 5th edition of this landmark publication, offering an expanded and updated overview of the global landscape of thalassaemia prevention, control, and clinical management across more than 70 countries where the disease is prevalent.

Building on the strong foundation of previous editions, the GTR 2025 provides comprehensive, evidence-based information, covering key areas that shape the lives and health outcomes of people living with thalassaemia. These include prevention programmes, clinical management practices, blood safety, and health system responses, as well as the disease’s economic and social burden, including the cost of care and broader social determinants of health.

In addition, the Review includes significant updates to existing chapters and expanded analyses, particularly regarding the epidemiology and global distribution of thalassaemia, offering deeper insights into emerging trends and evolving healthcare needs across regions worldwide.

Infographics

The Global Thalassaemia Review’s Infographics underline the most substantial data on thalassaemia that this landmark report has exposed. They also summarize the key points of TIF’s call on national governments globally to safeguard patients’ rights in health.

Availability

Blood insufficiency is experienced by more than 75% of patients in low- and middle- income countries.

Accessibility

More than 90% of the global patient population does not receive disease-specific social benefits.

Acceptability

Nationally coordinated and supported prevention programmes are absent in more than 80% of medium- and high- disease prevalence countries.

Quality

More than 60% of patients in low- and middle- income countries report recurring interruptions or postponements in their regular blood transfusions more than 15 times a year.

Progressive Realisation

In more than 90% of countries with medium- and high- disease prevalence, patients are still dependent on out of pocket expenses.

  • Availability

    Blood insufficiency is experienced by more than 75% of patients in low- and middle- income countries.

  • Accessibility

    More than 90% of the global patient population does not receive disease-specific social benefits.

  • Acceptability

    Nationally coordinated and supported prevention programmes are absent in more than 80% of medium- and high- disease prevalence countries.

  • Quality

    More than 60% of patients in low- and middle- income countries report recurring interruptions or postponements in their regular blood transfusions more than 15 times a year.

  • Progressive Realisation

    In more than 90% of countries with medium- and high- disease prevalence, patients are still dependent on out of pocket expenses.

Additional Material

WHO Director General Addresses the Global Thalassaemia Community

National Success Stories in the Prevention and Management of Thalassaemia

Milestones in Thalassaemia Treatment
by Prof John Porter

Global Thalassaemia Review High-level Event: The Premiere

Back to top button